Condition
Recurrent Vestibulopathy
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 3 (1)
Trial Status
Terminated1
Suspended1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04026516Not ApplicableSuspended
CAVA: Dizziness Trial
NCT01895400Phase 3TerminatedPrimary
Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy
Showing all 2 trials